ProfileGDS4814 / ILMN_1675577
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 78% 75% 75% 78% 77% 76% 74% 76% 76% 75% 78% 77% 76% 75% 79% 77% 77% 76% 78% 78% 76% 77% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)118.23678
GSM780708Untreated after 4 days (C2_1)95.62875
GSM780709Untreated after 4 days (C3_1)101.44775
GSM780719Untreated after 4 days (C1_2)122.53478
GSM780720Untreated after 4 days (C2_2)115.01277
GSM780721Untreated after 4 days (C3_2)105.15676
GSM780710Trastuzumab treated after 4 days (T1_1)92.608974
GSM780711Trastuzumab treated after 4 days (T2_1)107.02976
GSM780712Trastuzumab treated after 4 days (T3_1)103.3476
GSM780722Trastuzumab treated after 4 days (T1_2)96.44175
GSM780723Trastuzumab treated after 4 days (T2_2)124.59478
GSM780724Trastuzumab treated after 4 days (T3_2)111.62377
GSM780713Pertuzumab treated after 4 days (P1_1)109.00376
GSM780714Pertuzumab treated after 4 days (P2_1)101.88475
GSM780715Pertuzumab treated after 4 days (P3_1)128.08879
GSM780725Pertuzumab treated after 4 days (P1_2)112.39577
GSM780726Pertuzumab treated after 4 days (P2_2)115.84277
GSM780727Pertuzumab treated after 4 days (P3_2)107.80376
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)118.25878
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)118.8378
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)105.72376
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)112.57977
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)100.9175